

**RECORDATI: PUBLIC DISCLOSURE**

Milan, 19 March 2020 – Please be informed that, today, the Company made available to the public the following documents as approved by the Board of Directors on 18<sup>th</sup> March 2020:

- (i) the notice of call to the ordinary general meeting of the Shareholders' (29 April 2020 in a single call),
- (ii) the Directors' Reports relating to the following items of the agenda of the ordinary Shareholders' meeting:
  - item no. 1 (financial statement's approval and allocation of profit);
  - item no. 3 (appointment of the Board of Statutory Auditors);
  - item no. 4 (appointment of the audit firm); and
  - item no. 6 (authorization to the purchase and utilization of treasury stock).

The mentioned documents are published on the Company's website ([www.recordati.it](http://www.recordati.it), Section Investors, Shareholders' Meeting) and on the "1info" storage mechanism ([www.1info.it](http://www.1info.it)).

*Recordati, established in 1926, is an international pharmaceutical group, listed on the Italian Stock Exchange (Reuters RECI.MI, Bloomberg REC IM, ISIN IT 0003828271), with a total staff of more than 4,100, dedicated to the research, development, manufacturing and marketing of pharmaceuticals. Headquartered in Milan, Italy, Recordati has operations throughout the whole of Europe, including Russia, Turkey, North Africa, the United States of America, Canada, Mexico, some South American countries, Japan and Australia. An efficient field force of medical representatives promotes a wide range of innovative pharmaceuticals, both proprietary and under license, in a number of therapeutic areas including a specialized business dedicated to treatments for rare diseases. Recordati is a partner of choice for new product licenses for its territories. Recordati is committed to the research and development of new specialties with a focus on treatments for rare diseases. Consolidated revenue for 2019 was € 1,481.8 million, operating income was € 465.3 million and net income was € 368.9 million.*

For further information:

Recordati website: [www.recordati.com](http://www.recordati.com)

Investor Relations

Marianne Tatschke

(39)0248787393

e-mail: [investorelations@recordati.it](mailto:investorelations@recordati.it)

Media Relations

Studio Noris Morano

(39)0276004736, (39)0276004745

e-mail: [norismorano@studionorismorano.com](mailto:norismorano@studionorismorano.com)

**RECORDATI INDUSTRIA CHIMICA E FARMACEUTICA S.p.A.**

Sede Legale  
VIA M. CIVITALI, 1  
20148 MILANO, ITALIA  
TEL. (39) 0248787.1  
FAX (39) 0240073747

CAPITALE SOCIALE € 26.140.644,50 i.v.  
REG. IMP. MILANO, MONZA, BRIANZA e LODI 00748210150  
CODICE FISCALE/P. IVA 00748210150  
R.E.A. MILANO 401832